Buclizine
An antihistamine with antiemetic, antivertigo, and mild anxiolytic properties, used to treat motion sickness, vertigo, and nausea. It acts by blocking histamine and muscarinic receptors in the central nervous system. It is also used as an appetite stimulant in some formulations.
Peso molecular
433,0000 g/mol
LogP
7,10
TPSA
6,50 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1
InChI
InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3
Molecular Formula
C28H33ClN2
HBD / HBA
- / 2
Enlaces Rotables
6
Átomos Pesados
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
An antihistamine with antiemetic, antivertigo, and mild anxiolytic properties, used to treat motion sickness, vertigo, and nausea. It acts by blocking histamine and muscarinic receptors in the central nervous system. It is also used as an appetite stimulant in some formulations.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Buclizine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201271. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6729. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="buclizine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/buclizine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/buclizine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/buclizine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="buclizine"></drugfyi-drug>